Back

The urgency to treat LDL-c post MI: The role of PCSK9 mAbs in reaching goals.

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Redefining intensive LDL-c management in high risk patients: The case for combination therapy Risk Factors and Prevention Open Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Derek Connolly

Midland Metropolitan University Hospital, Smethwick (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
LDL-c in the management of high CV risk: Changing the paradigm for prevention.
Professor K. Ray (London, GB)
Video
Presentation thumbnail
Expanding therapeutic options for lowering LDL-c: Where will bempedoic acid and inclisiran contribute.
Doctor C. Ballantyne (Houston, US)
Video
Presentation thumbnail
Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?
Professor J. Kastelein (Amsterdam, NL)
Video

Access the full session

Session thumbnail
Redefining intensive LDL-c management in high risk patients: The case for combination therapy
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Session
The strength of scientific integration

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources